Literature DB >> 11068554

Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3.

N Villamor1, D Costa, M Aymerich, J Esteve, A Carrió, M Rozman, J L Aguilar, B Falini, E Montserrat, E Campo, D Colomer.   

Abstract

The fusion protein, promyelocytic leukemia-retinoic acid receptor (PML-RAR)alpha, generated by the t(15;17) translocation has an abnormal cellular distribution with colocalization of RARalpha and PML proteins. We analyzed the immunostaining pattern of PML protein using the PG-M3 monoclonal antibody directed against the amino terminal portion of PML (retained in wild-type PML and PML-RARalpha fusion protein) in the diagnosis of acute promyelocytic leukemia (APL). In addition, we compared this test with other methods for detecting the PML-RARalpha fusion gene. A normal immunostaining pattern was observed in nonmyeloid disorders and in 78 of 111 acute myeloid leukemias (AMLs). A microgranular pattern was observed in 25 AMLs, all corresponding to APL. These results were concordant with the reverse transcriptase-polymerase chain reaction results for PML-RARalpha fusion gene. Only 1 case positive for the PML-RARalpha transcript showed a normal protein pattern by immunocytochemistry. PML immunostaining was helpful to rapidly differentiate 7 cases with borderline characteristics and to obtain the diagnosis in 2 cases with scarce material. The effectiveness and low cost of this technique support its routine use as a first-line procedure in the differential diagnosis of AML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068554     DOI: 10.1309/J6PU-3XY6-R0C3-NW26

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.

Authors:  Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 2.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

3.  Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?

Authors:  Panagiotis A Papamichalis; Kalliopi Zachou; Roidoula A Papamichali; Maria Ioannou; Nikolaos K Gatselis; George N Dalekos; George K Koukoulis
Journal:  J Transl Int Med       Date:  2021-03-31

4.  Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia.

Authors:  E H A Dekking; V H J van der Velden; R Varro; H Wai; S Böttcher; M Kneba; E Sonneveld; A Koning; N Boeckx; N Van Poecke; P Lucio; A Mendonça; L Sedek; T Szczepański; T Kalina; V Kanderová; P Hoogeveen; J Flores-Montero; M C Chillón; A Orfao; J Almeida; P Evans; M Cullen; A L Noordijk; P M Vermeulen; M T de Man; E P Dixon; W M Comans-Bitter; J J M van Dongen
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.